FDA approves Gilead’s Livdelzi for treatment of primary biliary cholangitis (Healio)

The FDA has approved Gilead Sciences’ drug Livdelzi (bulevirtide) for the treatment of primary biliary cholangitis (PBC), a chronic liver disease. Livdelzi is the first and only approved treatment specifically targeting patients with PBC who are inadequate responders to ursodeoxycholic acid (UDCA), the standard treatment. This approval provides a new option for patients with limited treatment alternatives, potentially improving outcomes for those with this challenging condition.